Response to anti‐seizure medications in children carrying novel or previously reported HCN1 gene variants
Marium N. Khan, Nicholas P. Poolos · 2026
Read Response to anti‐seizure medications in children carrying novel or previously reported HCN1 gene variants by Marium N. Khan, Nicholas P. Poolos (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13418493.txt.
Introduction
Khan and Poolos surveyed families in 2026 about seizure drugs for children with epilepsy caused by HCN1 gene variants. HCN1 variants cause a syndrome of early epilepsy and developmental disability that often resists drugs. The team built a registry of ten children through a parent community and reviewed surveys plus medical records.
Five of the children's variants had never been reported before. Variants sitting in the channel's membrane-spanning region caused more severe disease than variants elsewhere. Children given lamotrigine or oxcarbazepine had more frequent seizures. Children given valproate or clobazam improved, and two became seizure-free on those drugs. The authors note the pattern resembles Dravet syndrome, another severe early epilepsy, hinting at shared mechanisms. They present the survey as practical guidance for drug choice in this rare syndrome, while urging confirmatory studies.
Catalog record
| CREATOR | Marium N. Khan, Nicholas P. Poolos |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Response to anti‐seizure medications in children carrying novel or previously reported HCN1 gene variants Authors: Marium N. Khan, Nicholas P. Poolos Published: 2026 ABSTRACT AbstractObjectiveVariants in the HCN1 gene cause a syndrome of childhood epilepsy and developmental disability with a broad phenotypic range. Many affected children manifest with early infantile epileptic encephalopathy (EIEE) and highly drug‐resistant epilepsy. There are anecdotal reports that seizures in this syndrome are exacerbated by some anti‐seizure medications (ASMs), including lamotrigine and lacosamide. However, the efficacy of most ASMs in this disorder is unknown. We sought to understand which ASMs were most effective.MethodsWe compiled a registry of 10 children with HCN1 variants and refractory epilepsy via outreach to parent members of an online social affinity group, and from unsolicited parent outreach to us. Parents filled out an eight‐page survey detailing their child's and parents' genetic testing results, child's developmental status, and response to ASMs. Outside medical records were provided that documented genetic testing results.ResultsFive of these variants had not been previously reported in the literature. Of these, there was phenotypic variability depending on where the variant mapped on the HCN1 ion channel structure, with variants mapping to an ion channel transmembrane domain causing more severe phenotypes. Subjects given lamotrigine or oxcarbazepine had exacerbated seizure frequency whereas those exposed to valproate or clobazam had improved seizure frequency, with two subjects becoming seizure‐free.SignificanceWe report here five novel HCN1 variants. We also provide a novel survey of ASM efficacy. These trends in ASM efficacy are similar to what has been observed in Dravet syndrome, another EIEE, raising questions about potential common pathogenic mechanisms at a cellular level.Plain Language SummaryWe surveyed families whose children had been diagnosed with a rare epilepsy syndrome due to mutations in the HCN1 gene. In reviewing their genetic testing results, we discovered five new gene mutations (variants) that had not been previously reported. We also asked which anti‐seizure medications had been most effective: they cited valproate and clobazam as most effective, while lamotrigine and oxcarbazepine made seizures worse. Key points We surveyed families of children with HCN1 variants and epilepsy. In our registry of 10 subjects, we discovered five novel HCN1 variants. HCN1 variants mapping to transmembrane regions of the ion channel were associated with more severe phenotypes than variants mapping to other areas of the HCN1 channel.Valproate and clobazam were the most effective anti‐seizure medications in reducing seizure frequency, whereas lamotrigine and oxcarbazepine exacerbated seizures. Key points We surveyed families of children with HCN1 variants and epilepsy. In our registry of 10 subjects, we discovered five novel HCN1 variants. HCN1 variants mapping to transmembrane regions of the ion channel were associated with more severe phenotypes than variants mapping to other areas of the HCN1 channel.Valproate and clobazam were the most effective anti‐seizure medications in reducing seizure frequency, whereas lamotrigine and oxcarbazepine exacerbated seizures. We surveyed families of children with HCN1 variants and epilepsy. In our registry of 10 subjects, we discovered five novel HCN1 variants. We surveyed families of children with HCN1 variants and epilepsy. In our registry of 10 subjects, we discovered five novel HCN1 variants. HCN1 variants mapping to transmembrane regions of the ion channel were associated with more severe phenotypes than variants mapping to other areas of the HCN1 channel. HCN1 variants mapping to transmembrane regions of the ion channel were associated with more severe phenotypes than variants mapping to other areas of the HCN1 channel. Valproate and clobazam were the most effective anti‐seizure medications in reducing seizure frequency, whereas lamotrigine and oxcarbazepine exacerbated seizures. Valproate and clobazam were the most effective anti‐seizure medications in reducing seizure frequency, whereas lamotrigine and oxcarbazepine exacerbated seizures. INTRODUCTION Variants in the human hyperpolarization activated, cyclic nucleotide‐gated cation channel type 1 (HCN1) gene cause a rare syndrome of early childhood epileptic encephalopathy manifested in many patients by medically refractory epilepsy and developmental disability (DD). 1 In most probands, HCN1 variants arise de novo without parental inheritance and cause onset of seizures and developmental delay or regression in the first year of life. The syndrome resembles in many ways Dravet syndrome (DS), which mostly arises from variants in the voltage‐gated Na+ channel gene SCN1A. 2 However, some children with HCN1 variants exhibit a milder syndrome, without seizures but with an autistic behavioral phenotype. 3 Seizures in children with HCN1 variants generally prove to be medically refractory. Anecdotal reports suggest that anti‐seizure medications (ASMs) with mechanisms of action (MOAs) that target Na+ channels are ineffective in this disorder and may even exacerbate seizures. 3 , 4 However, it is unclear whether any of the 20 or more licensed ASMs demonstrate efficacy in this difficult to treat syndrome. We sought to address this knowledge gap by assembling a registry of children with HCN1 variants by contacting parents who had joined a social media affinity group for this disorder, and also through unsolicited outreach to us by other parents. These parents filled out a survey on the clinical characteristics of their affected children, results of genetic testing, and response to ASMs. The results of this survey disclosed several previously unreported HCN1 variants and found wide variation in the response to ASMs. Knowledge of these variations in ASM efficacy may be clinically useful in guiding their epilepsy treatment. METHODS We assembled a registry of 10 children with HCN1 variants by either reaching out to parents who were members of a Facebook affinity group, “HCN1 Warriors,” or from unsolicited contacts from parents to the senior author. We received Institutional Review Board approval from the University of Washington to acquire these families' self‐reported medical information. Parents gave written consent to join the study and filled out an eight‐page survey (Supporting Information) detailing their child's and parents' genetic testing results, child's developmental status, and response to ASMs. In addition, outside medical records were provided that documented genetic testing results. RESULTS The demographics of the study population are shown in Table 1. Of the 10 subjects, five had HCN1 variants previously reported in the literature: M153I, S272P, M305L, I380F, and A387S. These variants all resulted in heterozygous, de novo single amino acid substitutions on the HCN1 protein sequence. All of these were associated with medically refractory epilepsy and moderate‐to‐severe DD. We also identified five subjects with novel HCN1 variants that have not been previously reported in the literature to the best of our knowledge. One subject was compound heterozygous for M215V amino acid substitution (paternally inherited) plus a deletion at p.73‐74 (maternally inherited). The remainder had heterozygous amino acid substitutions at M215V, M287L, F389S, and A670T. All subjects had associated DD ranging from mild to severe, with the exception of subject #10 (A670T) who was developmentally normal, even though that subject had epilepsy. TABLE 1HCN1 variant demographics.SubjectVariantGenderAge at seizure onsetAge at survey (year)Inheritance classificationGenetic testing methodPathogenicityDevelopmental disability1a M153I c.459G>C F5 months10De novoMultiple gene panelLikely pathogenicModerate2 M215V c.643A>G/ p.73‐74del c.218_223delGCGGCG F10 months5 Familial: Pat.: M215V Mat.: p.73‐74del Whole exome sequencing M215V: VUS p.73‐74del: likely benign Severe3 M215V c.643A>G M9 months4Familial: Mat.Whole exome sequencingVUS versus likely benignMild4b S272P c.814 T>C M4 months5De novoExome slicingPathogenicModerate5 M287L c.859A>C M5 years6Unknown/adoptedWhole genome sequencingVUSMild6a,c M305L c.913A>G/T F3 months4De novoMultiple gene panelLikely pathogenicSevere7d I380F c.1138A>T F3 months4De novoWhole exome sequencingPathogenicSevere8e,f A387S C.1159G>T M3 months2De novoWhole exome sequencingLikely pathogenicModerate9 F389S c.1166 T>C